Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amylyx Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Amylyx Pharmaceuticals, Inc.’s stock price such as:

• Amylyx Pharmaceuticals, Inc.’s current stock price and volume
• Why Amylyx Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for AMLX from analysts
• AMLX’s stock price momentum as measured by its relative strength

About Amylyx Pharmaceuticals, Inc. (AMLX)

Before we jump into Amylyx Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Amylyx Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amylyx Pharmaceuticals, Inc..

Amylyx Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of April 24, 2026, 10:15 AM, CST, Amylyx Pharmaceuticals, Inc.’s stock price was $17.040.

Amylyx Pharmaceuticals, Inc. is down 1.62% from its previous closing price of $17.320.

During the last market session, Amylyx Pharmaceuticals, Inc.’s stock traded between $17.040 and $17.530. Currently, there are approximately 109.84 million shares outstanding for Amylyx Pharmaceuticals, Inc..

Amylyx Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Amylyx Pharmaceuticals, Inc. Stock Price History

Amylyx Pharmaceuticals, Inc.’s (AMLX) price is currently up 22.59% so far this month.

During the month of April, Amylyx Pharmaceuticals, Inc.’s stock price has reached a high of $18.610 and a low of $13.880.

Over the last year, Amylyx Pharmaceuticals, Inc. has hit prices as high as $18.605 and as low as $4.200. Year to date, Amylyx Pharmaceuticals, Inc.’s stock is up 41.06%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amylyx Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 23, 2026, there were 0 analysts who downgraded Amylyx Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Amylyx Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amylyx Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amylyx Pharmaceuticals, Inc. (AMLX) by visiting AAII Stock Evaluator.

Relative Price Strength of Amylyx Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 23, 2026, Amylyx Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 24.97%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Amylyx Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amylyx Pharmaceuticals, Inc. Stock Price: Bottom Line

As of April 24, 2026, Amylyx Pharmaceuticals, Inc.’s stock price is $17.040, which is down 1.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amylyx Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.